MaxCyte Inc logo

MXCT - MaxCyte Inc News Story

410p -8.0  -1.9%

Last Trade - 23/10/20

Small Cap
Market Cap £276.4m
Enterprise Value £250.9m
Revenue £18.5m
Position in Universe 677th / 1805

MaxCyte, Inc. MaxCyte, Inc. - MXCR - Director/PDMR Shareholding

Thu 1st October, 2020 7:00am
For best results when printing this announcement, please click on link below:

RNS Number : 6925A  MaxCyte, Inc.  01 October 2020




MaxCyte, Inc.

("MaxCyte" or the "Company")


Director Dealings


Maryland, USA - 1 October 2020: MaxCyte (LSE: MXCT, MXCS), the global
cell-based medicines and life sciences company, announces that J. Stark
Thompson, Non-Executive Chairman of the Company, has exercised options over
25,000 shares of common stock of 0.1 pence of the Company ("Common Stock")
("Exercise"). In order to fund a near term personal tax liability, the 25,000
new shares of Common Stock issued pursuant to the Exercise ("New Common
Stock") have today been sold by Dr Thompson at a price of £3.55 pence per
Common Stock ("Sale"). Dr Thompson has no current intention of making further
sales of MaxCyte shares.


Following the Exercise and Sale, Dr Thompson's holding of Common Stock remains
unchanged at a total of 110,918 Common Stock representing a total of 0.14% of
the issued share capital of the Company. Dr Thompson holds a further
241,333 options over Common Stock.

Total voting rights

The New Common Stock will be allocated out of the common stock the subject of
the block listing announced on 2 May 2017. The New Common Stock will
rank pari passu with the existing shares of common stock of the Company. The
total issued stock capital of the Company following the above will be
77,305,169 shares of common stock. Shareholders in the Company may use this
figure as the denominator for the calculations by which they will determine if
they are required to notify their interest in, or a change to their interest
in, the stock capital of the Company.

The number of unrestricted shares of Common Stock trading under the symbol
'MXCT' is 67,405,080 and the number of restricted shares of Common Stock
trading under the symbol 'MXCS' is 9,900,089.

This announcement contains inside information for the purposes of Article 7 of
Regulation (EU) No 596/2014 ("MAR").


 1   Details of the person discharging managerial responsibilities/person closely
 a)  Name                                                         J. Stark Thompson
 2   Reason for the notification
 a)  Position/status                                              Non-Executive Chairman and PDMR
 b)  Initial notification/Amendment                               Initial notification
 3   Details of the issuer, emission allowance market participant, auction
     platform, auctioneer or auction monitor
 a)  Name                                                         MaxCyte, Inc.
 b)  LEI                                                          54930053YHXULRFCU991
 4   Details of the transaction(s): section to be repeated for (i) each type of
     instrument; (ii) each type of transaction; (iii) each date; and (iv) each
     place where transactions have been conducted
 a)  Description of the financial instrument, type of instrument  Ordinary shares of 0.1 pence each

 b)  Identification Code                                          US57777K1060
 c)  Nature of the transaction                                    Exercise of options and Sale of Common Stock by PDMR
 d)  Price(s) and volume(s)                                       Price(s)                     Volume(s)
     £3.55                                                                                     25,000

 e)  Aggregated information                                       N/A (Single Transaction)

     - Aggregated volume

     - Price
 f)  Date of the transaction                                      1.10.20
 g)  Place of the transaction                                     London Stock Exchange, AIM Market (XLON)



About MaxCyte

MaxCyte is a clinical-stage global cell-based therapies and life sciences
company. As the inventors of the premier cell-engineering enabling technology,
the Company helps bring the promise of next-generation cell and gene-editing
therapies to life. The Company's technology is currently being deployed by
leading drug developers worldwide, including all of the top ten global
biopharmaceutical companies. MaxCyte licences have been granted for more than
120 cell therapy programmes, with more than 90 licensed for clinical use, and
the Company has now entered into eleven clinical/commercial license
partnerships with leading cell therapy and gene editing developers. MaxCyte
was founded in 1998, is listed on the London Stock Exchange (AIM:MXCT, MXCL)
and is headquartered in Gaithersburg, Maryland, US. For more information,
visit (  .

 For further information, please contact:

 MaxCyte Inc.                                   +1 301 944 1660

 Doug Doerfler, Chief Executive Officer

 Amanda Murphy, Chief Financial Officer

 Nominated Adviser and Joint Corporate Broker   +44 (0)20 7886 2500

 Panmure Gordon

 Emma Earl

 Freddy Crossley

 Corporate Broking

 Rupert Dearden

 Joint Corporate Broker                         +44 (0)20 7260 1000

 Numis Securities Limited

 James Black

 Duncan Monteith
 Financial PR Adviser                            +44 (0)203 709 5700

 Consilium Strategic Communications   

 Mary-Jane Elliott

 Chris Welsh

 Sukaina Virji









This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact (
 or visit (

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (
© Stockopedia 2020, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.